Insider Buying: Boston Scientific (NYSE:BSX) Director Acquires 2,250 Shares of Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger bought 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.

Boston Scientific Price Performance

Shares of BSX traded up $0.41 during mid-day trading on Thursday, reaching $57.08. The stock had a trading volume of 12,837,051 shares, compared to its average volume of 16,615,801. The firm has a market cap of $84.84 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 1.04 and a beta of 0.62. Boston Scientific Corporation has a 12 month low of $52.52 and a 12 month high of $109.50. The business has a fifty day moving average of $62.46 and a 200 day moving average of $80.71. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

A number of brokerages have issued reports on BSX. Wall Street Zen lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. Canaccord Genuity Group cut their price objective on shares of Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. JPMorgan Chase & Co. cut their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Finally, Weiss Ratings lowered shares of Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $92.71.

Institutional Trading of Boston Scientific

Institutional investors have recently bought and sold shares of the stock. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter worth $26,000. Murphy & Mullick Capital Management Corp lifted its position in Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the last quarter. Swiss RE Ltd. bought a new stake in Boston Scientific in the fourth quarter worth $26,000. United Community Bank lifted its position in Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 147 shares during the last quarter. Finally, Colonial Trust Co SC lifted its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Multiple Boston Scientific directors bought shares this week, including David C. Habiger, Edward J. Ludwig, and Cheryl Pegus. Insider purchases are often viewed as a sign of management confidence in the company’s outlook and can support sentiment around the stock.
• Positive Sentiment: Boston Scientific reported positive pivotal trial results for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. The FRACTURE trial met all primary safety and effectiveness endpoints, which strengthens the case for a future regulatory submission and supports the company’s growth story in interventional cardiology.
• Neutral Sentiment: Baird kept an Outperform rating on Boston Scientific, though it trimmed its price target to $75 from $78. That suggests the firm still sees upside, but the lower target may temper enthusiasm somewhat.
• Negative Sentiment: Recent commentary also pointed to Boston Scientific having fallen on weak results, and the stock remains well below its longer-term moving averages. That indicates investors are still weighing execution concerns and broader pressure on the shares despite the upbeat insider and clinical developments.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.